Veracyte, Inc. (VCYT) Stock Price & Analysis
Veracyte, Inc. (VCYT) fell 2.19% to USD 56.61 as of July 25, 2026 at 07:48 UTC, according to Nexqual real-time market data.
VCYT last closed at USD 57.88; the session ranged USD 56.35–58.55 on volume of 589,509 shares. Market capitalization is $4.52B, with a 52-week range of USD 22.92–60.91 (NGM). Source: Nexqual, July 25, 2026 at 07:48 UTC.
Key Statistics (as of July 25, 2026 at 07:48 UTC)
| Price | USD 56.61 |
|---|---|
| Change | ▼ 2.19% (down) |
| Previous Close | USD 57.88 |
| Open | USD 58.55 |
| Day Range | USD 56.35 – 58.55 |
| 52-Week Range | USD 22.92 – 60.91 |
| Volume | 589,509 shares |
| Market Cap | $4.52B |
| Exchange | NGM |
Technical Analysis (VCYT)
Nexqual's technical model rates VCYT "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 07:48 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.88 (neutral) |
| vs SMA50 | Above (USD 51.83) |
| MACD | 1.68 (positive) |
Analyst Ratings (VCYT)
Wall Street analysts rate VCYT "Buy" based on 11 analysts, with a mean price target of USD 56.55 (range USD 45–70), per Nexqual as of July 25, 2026 at 07:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 56.55 |
| High Target | USD 70 |
| Low Target | USD 45 |
| Buy / Hold / Sell | 10 / 1 / 1 |
Earnings (VCYT)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 0.43 |
| Revenue Estimate | $144.48M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.52 vs est 0.33 ▲ beat |
| 2025-12-31 | USD 0.53 vs est 0.41 ▲ beat |
| 2025-09-30 | USD 0.51 vs est 0.32 ▲ beat |
| 2025-06-30 | USD 0.44 vs est 0.3 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:48 UTC.
Financials & Fundamentals (VCYT)
| Total Revenue | $541.74M |
|---|---|
| Revenue Growth (YoY) | +21.50% |
| Gross Margin | +72.91% |
| Operating Margin | +16.28% |
| Profit Margin | +16.25% |
| ROE | +6.93% |
| Debt / Equity | 2.93 |
| Current Ratio | 9.31 |
| Total Cash | $439.06M |
| Total Debt | $39.33M |
| Free Cash Flow | $104.51M |
Source: Nexqual, July 25, 2026 at 07:48 UTC.
Financial Health Score (VCYT)
Nexqual rates Veracyte, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 07:48 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 73%, operating 16% |
| Balance Sheet | Strong — $439M cash vs $39M debt, net cash position |
| Cash Flow | Strong — FCF $105M, 20% margin |
| Efficiency | Mixed — ROE 7%, ROA 3.8% |
Ownership (VCYT)
| Insider Ownership | +0.54% |
|---|---|
| Institutional Ownership | +113.48% |
| Shares Outstanding | 79.79M |
| Float | 79.28M |
| Short % of Float | +9.90% |
Source: Nexqual, July 25, 2026 at 07:48 UTC.
Leadership (VCYT)
Veracyte, Inc. is led by Marc A. Stapley (age 55), CEO & Director, per Nexqual as of July 25, 2026 at 07:48 UTC.
| CEO & Director | Marc A. Stapley (age 55) |
|---|---|
| Executive VP & CFO | Rebecca Chambers (age 47) |
| Chief Scientific & Medical Officer | Phillip G. Febbo (age 59) |
| Senior Vice President of Global Operations | Keith Gligorich |
| Director of Investor Relations | Kelly Gura |
Major Backers & Investors (VCYT)
Notable institutional backers of Veracyte, Inc. include FMR, LLC, Artisan Partners Limited Partnership, ARK Invest, according to Nexqual as of July 25, 2026 at 07:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 9.73% |
| Artisan Partners Limited Partnership | 8.48% |
| ARK Invest | 5.26% |
| Wellington Management | 3.21% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 3.11% |
| First Trust Advisors LP | 2.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 24.88% |
| Vanguard Group | 17.67% |
| State Street | 8.19% |
| Dimensional Fund Advisors | 3.61% |
Source: Nexqual, July 25, 2026 at 07:48 UTC.
From Veracyte, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We rely on sole suppliers for critical supply of reagents, equipment and other materials and services that we use to perform our CLIA tests as well as to satisfy demand for our Prosigna test kits, service kits and service on the nCounter Analysis System.
- Certain of our products are regulated as IVD MDs, including Prosigna and the nCounter Analysis System.
- While we have developed alternate sourcing strategies for many materials, vendors and service providers, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDNA | CareDx, Inc. | USD 37.14 | ▼ 1.69% |
| TWST | Twist Bioscience Corporation | USD 90.27 | ▼ 4.18% |
| FATE | Fate Therapeutics, Inc. | USD 2.41 | ▼ 6.59% |
| TXG | 10x Genomics, Inc. | USD 46.27 | ▼ 1.66% |
| PSNL | Personalis, Inc. | USD 11.78 | ▼ 5.53% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:48 UTC. This page is informational and not investment advice.